Lisata Therapeutics Inc (AKA: Caladrius Biosciences Inc~Corniche Group Inc~NeoStem Inc) Profile last edited on: 6/9/2024
CAGE: 4LJL0
UEI: USWTE8MPR7H1
Business Identifier: Cellular therapies for oncology, immunology, and regenerative medicine sectors 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Multiple
Congr. District: 07
County: Somerset
Congr. District: 07
County: Somerset
Public Profile
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 1b/2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; HONEDRA, a recipient of SAKIGAKE designation critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and LSTA201, a CD34+ cell therapy for the treatment of chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
25-49Revenue Range
2.5M-5MVC funded?
YesPublic/Private
Publicly TradedStock Info
NASDAQ : LSTAIP Holdings
10-14Awards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2019 | 2 | NIH | $1,941,301 | |
| Project Title: Exploratory Clinical Study to Evaluate the Potential Bioactivity of CLBS14 in Patients with Coronary Microvascular Dysfunction | ||||
| 2015 | 1 | NIH | $300,000 | |
| Project Title: Development of Novel Therapeutic Agents That Target Cancer Stem Cells | ||||
| 2013 | 1 | NIH | $147,765 | |
| Project Title: Development Of Adult Pluripotent Very Small Embryonic Like (Vsel) Stem Cells To T | ||||
| 2013 | 2 | NIH | $595,252 | |
| Project Title: Development of Human; Autologous; Pluripotent Very Small Embryonic Like (Vsels) S | ||||
| 2013 | 2 | NIH | $1,330,600 | |
| Project Title: Repair Of Boney Defects By Human Stem Cells | ||||
Key People / Management
David J Mazzo -- President and Chief Executive Officer
Robin L Smith -- Chairman & CEO
Timothy C Fong -- Vice President - Technology & Product Development, Progenitor Cell Therapy
George S Goldberger -- Vice President � Business Development, Progenitor Cell Therapy
Hans Keirstead
Daryl LeSueur -- Vice President � Manufacturing Operations, Progenitor Cell Therapy
Jeffrey Liter -- Chief Operating Officer, Progenitor Cell Therapy
Douglas W Losordo
Larry A May -- Chief Financial Officer
Andrew L Pecora -- Chief Medical Officer and Director
Stephen W Potter -- Executive Vice President
Robert A Preti -- President, Progenitor Cell Therapy
Denis O Rodgerson
Jonathan Sackner-Bernstein -- Vice President, Clinical Development and Regulatory Affairs
Martin E Schmieg -- Vice President, Corporate Development
Joseph Talamo -- Vice President, Corporate Controller and Chief Accounting Officer
Catherine M Vaczy -- Vice President and General Counsel
Mark Westgate -- Vice President - Finance, Progenitor Cell Therapy
Robin L Smith -- Chairman & CEO
Timothy C Fong -- Vice President - Technology & Product Development, Progenitor Cell Therapy
George S Goldberger -- Vice President � Business Development, Progenitor Cell Therapy
Hans Keirstead
Daryl LeSueur -- Vice President � Manufacturing Operations, Progenitor Cell Therapy
Jeffrey Liter -- Chief Operating Officer, Progenitor Cell Therapy
Douglas W Losordo
Larry A May -- Chief Financial Officer
Andrew L Pecora -- Chief Medical Officer and Director
Stephen W Potter -- Executive Vice President
Robert A Preti -- President, Progenitor Cell Therapy
Denis O Rodgerson
Jonathan Sackner-Bernstein -- Vice President, Clinical Development and Regulatory Affairs
Martin E Schmieg -- Vice President, Corporate Development
Joseph Talamo -- Vice President, Corporate Controller and Chief Accounting Officer
Catherine M Vaczy -- Vice President and General Counsel
Mark Westgate -- Vice President - Finance, Progenitor Cell Therapy
